Works matching IS 21641153 AND DT 2018 AND VI 8 AND IP 1
Results: 22
Imfinzi First Treatment Approved to Reduce Disease Progression in Unresectable Stage III NSCLC After Chemoradiation.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 50
- Publication type:
- Article
Erleada First Therapy Approved for Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 50
- Publication type:
- Article
Zytiga Receives New Indication, with Prednisone, for Metastatic, High-Risk Castration-Sensitive Prostate Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 49
- Publication type:
- Article
Lutathera First Radioactive Drug Approved for Adults with Gastroenteropancreatic Neuroendocrine Tumors.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 49
- Publication type:
- Article
Gilotrif Receives New Indication as First-Line Treatment for Metastatic NSCLC with Nonresistant EGFR Mutations.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 48
- Publication type:
- Article
Lynparza First Treatment Approved for Patients with Germline BRCA-Positive Metastatic Breast Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 48
- Publication type:
- Article
The Cost of Hematopoietic Stem-Cell Transplantation in the United States.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 40
- By:
- Publication type:
- Article
Aplastic Anemia in a Patient with Anaplastic Oligodendroglioma Postradiation and Concurrent Temozolomide Therapy: Case Report and Review of the Literature.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 34
- By:
- Publication type:
- Article
The Value of Pre-FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 31
- By:
- Publication type:
- Article
Prevention of Thromboembolism in Patients with Multiple Myeloma.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 26
- By:
- Publication type:
- Article
Encouraging Efficacy and Safety with Enasidenib or Ivosidenib plus Azacitidine in Patients with Newly Diagnosed AML.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 25
- Publication type:
- Article
Safety and Tolerability of Midostaurin from Expanded Treatment Protocol in Patients with FLT3 Mutation-Positive, Newly Diagnosed AML.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 25
- Publication type:
- Article
Enasidenib Monotherapy Is Well-Tolerated and Active in Older Patients with Untreated mIDH2 AML.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 24
- Publication type:
- Article
Nivolumab plus Azacitidine Shows Encouraging Activity in R/R AML or as Frontline Therapy in Elderly Patients with AML.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 24
- Publication type:
- Article
Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with...
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 23
- Publication type:
- Article
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 23
- Publication type:
- Article
Adverse Events, Resource Use, and Economic Burden in Patients with Mantle-Cell Lymphoma in the United States.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 23
- Publication type:
- Article
Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle-Cell Lymphoma: A Pooled Analysis.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 22
- Publication type:
- Article
Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 22
- Publication type:
- Article
Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 22
- Publication type:
- Article
Microbial Growth of Single-Dose Antineoplastic Drug Vials at 28 Days.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 17
- By:
- Publication type:
- Article
Impact of Pharmacist-Driven Educational Intervention on Documentation of Bowel Function Assessment in Patients with Cancer Who Are Using Opioids.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 13
- By:
- Publication type:
- Article